Skip to main content
main-content
Top

15-06-2020 | ADA 2020 | Conference coverage | News

News in brief

Empagliflozin delivers cardiovascular benefits within 3 weeks

Author:
Eleanor McDermid

medwireNews: A post-hoc analysis of the EMPA-REG OUTCOME trial shows the first benefits of empagliflozin appearing within the third week of taking the sodium-glucose cotransporter 2 inhibitor.

The earliest benefit appeared at day 17, when the reduction in heart failure hospitalization first achieved statistical significance, at a 90% reduction in risk for people with type 2 diabetes assigned to take empagliflozin rather than placebo.

The positive effect of empagliflozin on cardiovascular death took longer to appear, achieving a significant 72% reduction by day 59, which stabilized to a 40% reduction by day 317. The risk reduction for the combined outcome was significant by day 27.

“Taken together, these findings demonstrate the rapidity of benefit of empagliflozin in reducing the risk of cardiovascular and heart failure outcomes in this trial,” said Subodh Verma (University of Toronto, Ontario, Canada), who presented the results at the virtual ADA 80th Scientific Sessions.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

ADA Scientific Sessions; 12–16 June 2020

EASD Annual Meeting 2021 coverage

Access all of our ongoing coverage including the latest news and expert video interviews.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.